Meeting
2020 ASCO Virtual Scientific Program
A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases.
Authors
Luke Maese
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Luke Maese , Rachel E. Rau , Elizabeth A. Raetz , Tong Lin , Pil Kim , Reddy Chandula , Sherrie McClung , Julie Gray , L. Mi Rim Choi , Mignon L. Loh , Peter C. Adamson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04145531
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS7568)
DOI
10.1200/JCO.2020.38.15_suppl.TPS7568
Abstract #
TPS7568
Poster Bd #
341
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Forecasting asparaginase quantity required to treat pediatric ALL in LMICs using ACCESS FORxECAST.
First Author: Terence M. Hughes
Poster
2018 ASCO Annual Meeting
Pharmacodynamic characterization of eryaspase (L-asparaginase encapsulated in red blood cells) in combination with chemotherapy in a phase 2/3 trial in patients with relapsed acute lymphoblastic leukemia (NCT01518517).
First Author: Iman El-Hariry
Poster
2013 ASCO Annual Meeting
Safety of asparaginase Erwinia chrysanthemi in a compassionate-use trial: Subanalysis of the adolescent/young adult (AYA) and adult patient (Pt) population.
First Author: Paul V. Plourde
Poster
2012 ASCO Annual Meeting
Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG e. coli l-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4.
First Author: Anne L. Angiolillo